San Diego-based Tear Film Innovations Inc. said it has raised $9 million in a Series A round.

The company’s iLux system treats blocked meibomian glands, a leading cause of dry eye disease, through heating and compression of affected eyelids. The device is under review by the U.S. Food and Drug Administration.

The financing round, announced Nov. 7, was led by Visionary Ventures Fund LP, an ophthalmology-focused venture capital firm based in Orange County, and Tigris Ventures LLC, a venture fund and medical device incubator in Del Mar.

Tigris principals were involved in Tear Film’s founding, the company said in a recent statement announcing the financing round’s completion.